What do systematic reviews say?

Aspirin 1000 mg vs placebo

• Aspirin for acute treatment of episodic tension‐type headache in adults 2017 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 723 participants
  Low

Aspirin 1000 mg vs placebo

• Aspirin for acute treatment of episodic tension‐type headache in adults 2017 · Cochrane Headline outcomes only
  no estimate extracted
  4 studies · 767 participants
  Very low

Aspirin 1000 mg vs placebo

• Aspirin for acute treatment of episodic tension‐type headache in adults 2017 · Cochrane Headline outcomes only
  no estimate extracted
  4 studies · 767 participants
  Very low

Low‐dose aspirin vs placebo or no treatment

Low‐dose aspirin showed no clear difference in live birth compared with placebo or no treatment (moderate certainty).

• Aspirin for in vitro fertilisation 2016 · Cochrane Headline outcomes only
  RR 0.91 [0.72, 1.15]
  3 studies · 1053 participants
  Moderate

Low‐dose aspirin vs placebo or no treatment

Low‐dose aspirin showed no clear difference in clinical pregnancy compared with placebo or no treatment (moderate certainty).

• Aspirin for in vitro fertilisation 2016 · Cochrane Headline outcomes only
  RR 1.03 [0.91, 1.17]
  10 studies · 2142 participants
  Moderate

Low‐dose aspirin vs placebo or no treatment

Low‐dose aspirin showed no clear difference in multiple pregnancy (on ultrasound) compared with placebo or no treatment (low certainty).

• Aspirin for in vitro fertilisation 2016 · Cochrane Headline outcomes only
  RR 0.67 [0.37, 1.25]
  2 studies · 656 participants
  Low

Low‐dose aspirin vs placebo or no treatment

Low‐dose aspirin showed no clear difference in miscarriage rate per woman compared with placebo or no treatment (low certainty).

• Aspirin for in vitro fertilisation 2016 · Cochrane Headline outcomes only
  RR 1.1 [0.68, 1.77]
  5 studies · 1497 participants
  Low

Low‐dose aspirin vs placebo or no treatment

It is very uncertain whether low‐dose aspirin changes ectopic pregnancy compared with placebo or no treatment (very low certainty).

• Aspirin for in vitro fertilisation 2016 · Cochrane Headline outcomes only
  RR 1.86 [0.75, 4.63]
  3 studies · 1135 participants
  Very low

Low‐dose aspirin vs placebo or no treatment

It is very uncertain whether low‐dose aspirin changes vaginal bleeding compared with placebo or no treatment (very low certainty).

• Aspirin for in vitro fertilisation 2016 · Cochrane Headline outcomes only
  RR 1.01 [0.14, 7.13]
  1 study · 487 participants
  Very low

Low‐dose aspirin vs placebo or no treatment

The review found no eligible studies for this question.

• Aspirin for in vitro fertilisation 2016 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Aspirin vs vitamin K antagonist (VKA)

It is very uncertain whether aspirin (ASA) changes all‐cause mortality compared with vitamin K antagonist (VKA) (very low certainty).

• Antithrombotic therapy for ambulatory patients with multiple myeloma receiving immunomodulatory agents 2021 · Cochrane Headline outcomes only
  RR 3 [0.12, 73.24]
  1 study · 440 participants
  Very low
• Antithrombotic therapy for ambulatory patients with multiple myeloma receiving immunomodulatory agents 2021 · Cochrane Headline outcomes only
  RR 0.5 [0.05, 5.47]
  1 study · 440 participants
  Very low

Aspirin vs vitamin K antagonist (VKA)

The review found no eligible studies for this question.

• Antithrombotic therapy for ambulatory patients with multiple myeloma receiving immunomodulatory agents 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Aspirin vs low molecular weight heparin

It is very uncertain whether aspirin (ASA) changes all‐cause mortality compared with low molecular weight heparin (LMWH) (very low certainty).

• Antithrombotic therapy for ambulatory patients with multiple myeloma receiving immunomodulatory agents 2021 · Cochrane Headline outcomes only
  RR 1 [0.06, 15.81]
  2 studies · 781 participants
  Very low
• Antithrombotic therapy for ambulatory patients with multiple myeloma receiving immunomodulatory agents 2021 · Cochrane Headline outcomes only
  RR 1 [0.06, 15.89]
  1 study · 440 participants
  Very low

Aspirin vs low molecular weight heparin

It is very uncertain whether aspirin (ASA) changes symptomatic deep vein thrombosis compared with low molecular weight heparin (LMWH) (very low certainty).

• Antithrombotic therapy for ambulatory patients with multiple myeloma receiving immunomodulatory agents 2021 · Cochrane Headline outcomes only
  RR 1.23 [0.49, 3.08]
  2 studies · 781 participants
  Very low
• Antithrombotic therapy for ambulatory patients with multiple myeloma receiving immunomodulatory agents 2021 · Cochrane Headline outcomes only
  RR 1.2 [0.53, 2.72]
  1 study · 440 participants
  Very low

Aspirin vs low molecular weight heparin

It is very uncertain whether aspirin (ASA) changes pulmonary embolism compared with low molecular weight heparin (LMWH) (very low certainty).

• Antithrombotic therapy for ambulatory patients with multiple myeloma receiving immunomodulatory agents 2021 · Cochrane Headline outcomes only
  RR 7.71 [0.97, 61.44]
  2 studies · 781 participants
  Very low
• Antithrombotic therapy for ambulatory patients with multiple myeloma receiving immunomodulatory agents 2021 · Cochrane Headline outcomes only
  RR 9 [0.49, 166.17]
  1 study · 440 participants
  Very low

Aspirin vs low molecular weight heparin

It is very uncertain whether aspirin (ASA) changes major bleeding compared with low molecular weight heparin (LMWH) (very low certainty).

• Antithrombotic therapy for ambulatory patients with multiple myeloma receiving immunomodulatory agents 2021 · Cochrane Headline outcomes only
  RR 6.97 [0.36, 134.11]
  2 studies · 781 participants
  Very low
• Antithrombotic therapy for ambulatory patients with multiple myeloma receiving immunomodulatory agents 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Aspirin vs low molecular weight heparin

It is very uncertain whether aspirin (ASA) changes minor bleeding compared with low molecular weight heparin (LMWH) (very low certainty).

• Antithrombotic therapy for ambulatory patients with multiple myeloma receiving immunomodulatory agents 2021 · Cochrane Headline outcomes only
  RR 1.42 [0.35, 5.78]
  2 studies · 781 participants
  Very low

Aspirin vs vitamin K antagonist (VKA)

It is very uncertain whether aspirin (ASA) changes symptomatic deep vein thrombosis compared with vitamin K antagonist (VKA) (very low certainty).

• Antithrombotic therapy for ambulatory patients with multiple myeloma receiving immunomodulatory agents 2021 · Cochrane Headline outcomes only
  RR 0.57 [0.24, 1.33]
  1 study · 440 participants
  Very low
• Antithrombotic therapy for ambulatory patients with multiple myeloma receiving immunomodulatory agents 2021 · Cochrane Headline outcomes only
  RR 0.71 [0.35, 1.44]
  1 study · 440 participants
  Very low

Aspirin vs low molecular weight heparin

The review found no eligible studies for this question.

• Antithrombotic therapy for ambulatory patients with multiple myeloma receiving immunomodulatory agents 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Aspirin vs vitamin K antagonist (VKA)

It is very uncertain whether aspirin (ASA) changes pulmonary embolism compared with vitamin K antagonist (VKA) (very low certainty).

• Antithrombotic therapy for ambulatory patients with multiple myeloma receiving immunomodulatory agents 2021 · Cochrane Headline outcomes only
  RR 1 [0.25, 3.95]
  1 study · 440 participants
  Very low
• Antithrombotic therapy for ambulatory patients with multiple myeloma receiving immunomodulatory agents 2021 · Cochrane Headline outcomes only
  RR 1 [0.25, 3.95]
  1 study · 440 participants
  Very low